The development of additional in vivo biomarkers for other brain pathologies such as synucleinopathy, TDP-43, and others that often co-occur with Alzheimer’s disease pathology47 is greatly needed to parse the effects of other neurodegenerative processes. Here, TARDBP is linked to synucleinopathy.